Login / Signup

Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.

Vincent GermainMarc ScherlingerThomas BarnetcheThierry Schaeverbekenull null
Published in: Annals of the rheumatic diseases (2018)
Keyphrases
  • computed tomography
  • body mass index
  • image quality
  • physical activity
  • weight loss
  • dual energy
  • contrast enhanced
  • weight gain
  • positron emission tomography
  • ulcerative colitis
  • magnetic resonance
  • body weight
  • pet ct